...
首页> 外文期刊>Microbial Cell Factories >Surface display of hirame novirhabdovirus (HIRRV) G protein in Lactococcus lactis and its immune protection in flounder ( Paralichthys olivaceus )
【24h】

Surface display of hirame novirhabdovirus (HIRRV) G protein in Lactococcus lactis and its immune protection in flounder ( Paralichthys olivaceus )

机译:乳酸乳球菌中的hirame novirhabdovirus(HIRRV)G蛋白的表面展示及其对比目鱼的免疫保护(Paralichthys olivaceus)。

获取原文

摘要

Hirame novirhabdovirus (HIRRV) can infect a wide range of marine and freshwater fish, causing huge economic losses to aquaculture industry. Vaccine development, especially oral vaccine, has become an effective and convenient way to control aquatic infectious diseases. HIRRV glycoprotein (G), an immunogenic viral protein is a potential vaccine candidate for prevention of the disease. Here, we aimed to construct a recombinant Lactococcus lactis strain expressing HIRRV-G on the cell surface as an oral vaccine to prevent HIRRV. Glycoprotein gene of HIRRV was successfully cloned and expressed in L. lactis NZ9000 in a surface-displayed form, yielding Ll:pSLC-G. An approximately 81?kDa recombinant G protein (containing LysM anchoring motif) was confirmed by SDS-PAGE, western blotting and mass spectrometry analysis. The surface-displayed G protein was also verified by immunofluorescence and flow cytometry assays. Furthermore, to evaluate the potential of Ll:pSLC-G as oral vaccine candidate, flounders were continuously fed with commercial diet pellets coated with 1.0?×?109 cfu/g of induced Ll:pSLC-G for 1?week. Four weeks later, booster vaccination was performed with the same procedure. Compared with the controls, Ll:pSLC-G elicited significantly higher levels of specific IgM against HIRRV in flounder gut mucus at the second week and in serum at the fourth week (p??0.05). Meanwhile, oral immunization with Ll:pSLC-G could provide 60.7% protection against HIRRV infection and a significantly lower virus load was detected than the controls on the third day post-challenge (p??0.01). Moreover, on the first day post 1-week feeding, approximately 104–105 recombinant L. lactis cells were detected in every gram of foregut, midgut and hindgut of flounder, which were mainly localized at the bottom of gut mucus layer; and on day 21, 102–103 L. lactis cells could still be recovered. HIRRV-G protein was successfully expressed on the surface of L. lactis cells, which could trigger mucosal and humoral immune response of flounder and provide considerable immune protection against HIRRV. It suggests that genetically engineered L. lactis expressing G protein can be employed as a promising oral vaccine against HIRRV infection.
机译:Hirame novirhabdovirus(HIRRV)可以感染多种海洋和淡水鱼类,给水产养殖业造成巨大的经济损失。疫苗的开发,特别是口服疫苗,已成为控制水生传染病的有效便捷的途径。 HIRRV糖蛋白(G)是一种免疫原性病毒蛋白,是预防该疾病的潜在疫苗候选者。在这里,我们旨在构建重组的乳酸乳球菌菌株在细胞表面表达HIRRV-G,作为预防HIRVV的口服疫苗。成功地克隆了HIRRV的糖蛋白基因,并以表面展示的形式在乳酸乳球菌NZ9000中表达,产生了Ll:pSLC-G。通过SDS-PAGE,蛋白质印迹和质谱分析证实了大约81kkDa的重组G蛋白(含有LysM锚定基序)。还通过免疫荧光和流式细胞术分析验证了表面展示的G蛋白。此外,为了评价L1:pSLC-G作为口服疫苗候选物的潜力,向比目鱼连续喂食1.0××109 cfu / g诱导的L1:pSLC-G包被的商业饲料颗粒1周。四周后,以相同的程序进行加强免疫。与对照相比,L1:pSLC-G在比目鱼肠粘液中和第二周血清中引起的针对HIRRV的特异性IgM水平明显升高(p <0.05)。同时,用L1:pSLC-G进行的口服免疫可提供针对HIRRV感染的60.7%的保护,并且在攻击后第三天检测到的病毒载量明显低于对照组(p≤0.01)。此外,在喂食1周后的第一天,在每克比目鱼的前肠,中肠和后肠中检测到约104-105个重组乳酸乳球菌细胞,这些细胞主要位于肠粘液层的底部。在第21天,仍可回收102-103个乳酸乳球菌细胞。 HIRRV-G蛋白成功地表达在乳酸乳球菌的表面,可以触发比目鱼的粘膜和体液免疫反应,并提供针对HIRRV的大量免疫保护。这表明表达基因工程的表达乳杆菌的G蛋白可用作抗HIRVV感染的有前途的口服疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号